Press Release
<< Back
Verastem Announces Presentations at the 2013 World Conference on Lung Cancer
Title: |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 as Maintenance Therapy in Subjects with Malignant Pleural Mesothelioma which has Not Progressed on at least 4 Cycles of Pemetrexed/Platinum Therapy (COMMAND) |
|
Abstract #: |
P2.14-014 |
|
Date and Time: |
Tuesday, October 29, 2013 9:30 – 4:30 PM | |
Session: |
Poster Session 2; Mesothelioma | |
Location: |
Exhibit Hall, Ground Level | |
Title: |
Malignant Mesothelioma Lacking Merlin Shows Enhanced Sensitivity to the FAK Inhibitor VS-6063: Evaluation of Merlin/NF2 Status in Clinical Samples | |
Abstract #: |
P2.06-048 | |
Date and Time: |
Tuesday, October 29, 2013 9:30 – 4:30 PM | |
Session: |
Poster Session 2; Prognostic and Predictive Biomarkers | |
Location: |
Exhibit Hall, Ground Level | |
About VS-6063
VS-6063 (defactinib) is an oral compound designed to target cancer stem
cells through the potent inhibition of focal adhesion kinase (FAK).
Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research by
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-6063,
or defactinib, and the Company’s FAK and diagnostic programs generally,
the timeline for clinical development and regulatory approval of the
Company’s compounds, the expected timing for the reporting of data from
ongoing studies, the structure of the Company’s planned clinical trials
and the Company’s ability to fund operations. The words “anticipate,”
“appear,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks that the
preclinical testing of the Company’s compounds and preliminary data from
clinical trials may not be predictive of the results or success of later
clinical trials, that data may not be available when we expect it to be,
that the Company will be unable to successfully complete the clinical
development of its compounds, including VS-6063, that the development of
the Company’s compounds will take longer or cost more than planned, and
that the Company’s compounds will not receive regulatory approval or
become commercially successful products. Other risks and uncertainties
include those identified under the heading “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com